{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T07:16:21Z","timestamp":1783581381843,"version":"3.55.0"},"reference-count":22,"publisher":"Georg Thieme Verlag KG","issue":"03","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Bayer"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Thromb Haemost"],"published-print":{"date-parts":[[2025,3]]},"abstract":"<jats:p>\n            Background\u2003In most patients with cancer-associated venous thromboembolism (CT), essentially those not at high risk of bleeding, guidelines recommend treatment with direct oral anticoagulants as an alternative to low-molecular-weight heparins (LMWHs). Population-based studies comparing these therapies are scarce.<\/jats:p><jats:p>\n            Objectives\u2003To compare the risk of venous thromboembolism (VTE) recurrences, significant bleeding, and all-cause mortality in patients with CT receiving rivaroxaban or LMWHs.<\/jats:p><jats:p>\n            Patients\/Methods\u2003Using UK Clinical Practice Research Datalink data from 2013 to 2020, we generated a cohort of patients with first CT treated initially with either rivaroxaban or LMWH. Patients were observed 12 months for VTE recurrences, significant bleeds (major bleeds or clinically relevant nonmajor bleeding requiring hospitalization), and all-cause mortality. Overlap weighted sub-distribution hazard ratios (SHRs) compared rivaroxaban with LMWH in an intention-to-treat analysis.<\/jats:p><jats:p>\n            Results\u2003The cohort consisted of 2,259 patients with first CT, 314 receiving rivaroxaban, and 1,945 LMWH, mean age 72.4 and 66.9 years, respectively. In the 12-month observational period, 184 person-years following rivaroxaban and 1,057 following LMWH, 10 and 66 incident recurrent VTE events, 20 and 102 significant bleeds, and 10 and 133 deaths were observed in rivaroxaban and LMWH users, respectively. The weighted SHR at 12 months for VTE recurrences in rivaroxaban compared with LMWH were 0.80 (0.37\u20131.73); for significant bleeds 1.01 (0.57\u20131.81); and for all-cause mortality 0.49 (0.23\u20131.06).<\/jats:p><jats:p>\n            Conclusion\u2003Patients with CT, not at high risk of bleeding, treated with either rivaroxaban or LMWH have comparable effectiveness and safety outcomes. This supports the recommendation that rivaroxaban is a reasonable alternative to LMWH for the treatment of CT.<\/jats:p>","DOI":"10.1055\/a-2259-0662","type":"journal-article","created":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T23:52:02Z","timestamp":1706831522000},"page":"265-277","source":"Crossref","is-referenced-by-count":11,"title":["Comparison of Clinical Outcomes in Patients with Active Cancer Receiving Rivaroxaban or Low-Molecular-Weight Heparin: The OSCAR-UK Study"],"prefix":"10.1055","volume":"125","clinical-trial-number":[{"clinical-trial-number":"nct05112666","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Alexander T.","family":"Cohen","sequence":"additional","affiliation":[{"name":"Department of Haematological Medicine, Guy's and St Thomas' NHS Foundation Trust, King's College London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7944-7347","authenticated-orcid":false,"given":"Christopher","family":"Wallenhorst","sequence":"additional","affiliation":[{"name":"Institute for Epidemiology, Statistics and Informatics GmbH, Frankfurt am Main, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcella","family":"Rivera","sequence":"additional","affiliation":[{"name":"Bayer AG, Berlin, Germany at the time of study conduct, currently affiliated to Janssen Research and Development, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cihan","family":"Ay","sequence":"additional","affiliation":[{"name":"Clinical Division of Haematology and Haemostaseology, Department of Medicine I, Medical University of Vienna, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernhard","family":"Schaefer","sequence":"additional","affiliation":[{"name":"Bayer AG, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khaled","family":"Abdelgawwad","sequence":"additional","affiliation":[{"name":"Bayer AG, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Psaroudakis","sequence":"additional","affiliation":[{"name":"Bayer AG, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gunnar","family":"Brobert","sequence":"additional","affiliation":[{"name":"Bayer AG, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders","family":"Ekbom","sequence":"additional","affiliation":[{"name":"Unit of Clinical Epidemiology, Department of Medicine, Karolinska Institute, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnes Y. Y.","family":"Lee","sequence":"additional","affiliation":[{"name":"Division of Hematology, University of British Columbia and BC Cancer, Vancouver, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9509-0998","authenticated-orcid":false,"given":"Alok A.","family":"Khorana","sequence":"additional","affiliation":[{"name":"Cleveland Clinic and Case Comprehensive Cancer Center, Cleveland, Ohio, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia","family":"Becattini","sequence":"additional","affiliation":[{"name":"Department of Internal and Emergency Medicine \u2013 Stroke Unit, University of Perugia, Perugia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Carrier","sequence":"additional","affiliation":[{"name":"Department of Medicine, Ottawa Hospital Research Institute at the University of Ottawa, Ottawa, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4868-7158","authenticated-orcid":false,"given":"Craig I.","family":"Coleman","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, School of Pharmacy, University of Connecticut, Storrs, Connecticut, United States"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6498-6428","authenticated-orcid":false,"given":"Carlos","family":"Martinez","sequence":"additional","affiliation":[{"name":"Institute for Epidemiology, Statistics and Informatics GmbH, Frankfurt am Main, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2024,4,8]]},"reference":[{"issue":"10","key":"ref1","doi-asserted-by":"crossref","first-page":"3484","DOI":"10.1182\/blood-2002-01-0108","article-title":"Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis","volume":"100","author":"P Prandoni","year":"2002","journal-title":"Blood"},{"issue":"01","key":"ref2","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1160\/TH15-08-0686","article-title":"Epidemiology of first and recurrent venous thromboembolism in patients with active cancer. A population-based cohort study","volume":"117","author":"A T Cohen","year":"2017","journal-title":"Thromb Haemost"},{"issue":"02","key":"ref3","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s11239-020-02180-x","article-title":"Cancer associated thrombosis in everyday practice: perspectives from GARFIELD-VTE","volume":"50","author":"J I Weitz","year":"2020","journal-title":"J Thromb Thrombolysis"},{"issue":"04","key":"ref4","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1182\/bloodadvances.2020003442","article-title":"American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer","volume":"5","author":"G H Lyman","year":"2021","journal-title":"Blood Adv"},{"issue":"03","key":"ref5","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/bloodadvances.2020003763","article-title":"American Society of Hematology 2021 guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19","volume":"5","author":"A Cuker","year":"2021","journal-title":"Blood Adv"},{"issue":"09","key":"ref6","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1111\/jth.14219","article-title":"Role of direct oral anticoagulants in the treatment of cancer-associated venous thromboembolism: guidance from the SSC of the ISTH","volume":"16","author":"A A Khorana","year":"2018","journal-title":"J Thromb Haemost"},{"issue":"07","key":"ref7","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1055\/s-0040-1712098","article-title":"Direct oral anticoagulants for the treatment of acute venous thromboembolism associated with cancer: a systematic review and meta-analysis","volume":"120","author":"M Giustozzi","year":"2020","journal-title":"Thromb Haemost"},{"issue":"08","key":"ref8","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3390\/cancers12082256","article-title":"Long-term treatment of cancer-associated thrombosis (CAT) beyond 6 months in the medical practice: USCAT, a 432-patient retrospective non-interventional study","volume":"12","author":"I Mah\u00e9","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"11","key":"ref9","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1253\/circj.CJ-19-0515","article-title":"Cancer-associated venous thromboembolism in the real world - From the COMMAND VTE registry","volume":"83","author":"J Sakamoto","year":"2019","journal-title":"Circ J"},{"issue":"01","key":"ref10","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1182\/blood-2021-151566","article-title":"Patient characteristics and temporal changes in anticoagulation treatment patterns in patients diagnosed with cancer-associated thrombosis: an Oscar-US Analysis","volume":"138","author":"C Coleman","year":"2021","journal-title":"Blood"},{"issue":"02","key":"ref11","first-page":"255","article-title":"Epidemiology of first and recurrent venous thromboembolism: a population-based cohort study in patients without active cancer","volume":"112","author":"C Martinez","year":"2014","journal-title":"Thromb Haemost"},{"issue":"04","key":"ref12","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","article-title":"Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients","volume":"3","author":"S Schulman","year":"2005","journal-title":"J Thromb Haemost"},{"issue":"03","key":"ref14","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1111\/bjh.16383","article-title":"Prediction of significant bleeding during vitamin K antagonist treatment for venous thromboembolism in outpatients","volume":"189","author":"C Martinez","year":"2020","journal-title":"Br J Haematol"},{"issue":"01","key":"ref15","first-page":"250","article-title":"Addressing extreme propensity scores via the overlap weights","volume":"188","author":"F Li","year":"2019","journal-title":"Am J Epidemiol"},{"issue":"23","key":"ref16","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1001\/jama.2020.7819","article-title":"Overlap weighting: a propensity score method that mimics attributes of a randomized clinical trial","volume":"323","author":"L E Thomas","year":"2020","journal-title":"JAMA"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1093\/biomet\/69.1.239","article-title":"Partial residuals for the proportional hazards model","volume":"69","author":"D Schoenfeld","year":"1982","journal-title":"Biometrika"},{"issue":"02","key":"ref18","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.jaccao.2022.10.014","article-title":"Effectiveness and safety of rivaroxban and low molecular-weight heparin in cancer-assocaited venous thromboembolism","volume":"5","author":"C I Coleman","year":"2023","journal-title":"JACC Cardiooncol"},{"issue":"09","key":"ref19","doi-asserted-by":"crossref","first-page":"5773","DOI":"10.1007\/s00432-022-04535-8","article-title":"DOAC in the treatment of cancer-associated venous thromboembolism: a retrospective cohort study beyond the guidelines","volume":"149","author":"M Cominacini","year":"2023","journal-title":"J Cancer Res Clin Oncol"},{"issue":"01","key":"ref20","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1007\/s11239-022-02717-2","article-title":"Net clinical benefit of DOACs vs. usual anticoagulation treatment in venous thromboembolism and active cancer: systematic review and meta-analysis","volume":"55","author":"H Michalopoulou","year":"2023","journal-title":"J Thromb Thrombolysis"},{"issue":"17","key":"ref21","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1056\/NEJMoa1915103","article-title":"Apixaban for the treatment of venous thromboembolism associated with cancer","volume":"382","author":"G Agnelli","year":"2020","journal-title":"N Engl J Med"},{"issue":"07","key":"ref22","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1056\/NEJMoa1711948","article-title":"Edoxaban for the treatment of cancer-associated venous thromboembolism","volume":"378","author":"G E Raskob","year":"2018","journal-title":"N Engl J Med"},{"issue":"20","key":"ref23","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1200\/JCO.2018.78.8034","article-title":"Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D)","volume":"36","author":"A M Young","year":"2018","journal-title":"J Clin Oncol"}],"container-title":["Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2259-0662.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T00:16:03Z","timestamp":1740528963000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2259-0662"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,1]]},"references-count":22,"journal-issue":{"issue":"03","published-online":{"date-parts":[[2025,2,25]]},"published-print":{"date-parts":[[2025,3]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2259-0662","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0340-6245","2567-689X"],"issn-type":[{"value":"0340-6245","type":"print"},{"value":"2567-689X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,2,1]]},"published":{"date-parts":[[2024,2,1]]}}}